Eye drop gel shows promise for skin graft healing, but trial stalls

NCT ID NCT03579160

Terminated Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether applying 0.25% timolol gel (a beta-blocker eye drop used for glaucoma) to skin grafts could improve healing and appearance after skin cancer surgery. Researchers planned to enroll 82 patients but stopped early with only 10 participants. The goal was to see if the gel helps wounds heal faster and look better compared to standard Vaseline dressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 0.25% timolol gel
What this could lead to: If it works, this could offer a simple, low-cost way to improve healing and cosmetic outcomes for skin grafts after cancer surgery.
What could go wrong: The trial was terminated early with only 10 participants, so results are very limited. It is unclear if timolol gel is truly effective or safe for this use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FULL THICKNESS SKIN GRAFT HEALING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

injury skin cancer Surgical Wound

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FULL THICKNESS SKIN GRAFT HEALING SURGICAL WOUND WOUND HEAL WOUND OF SKIN

Contacts and locations

Locations

Mohs and Dermatologic Surgery Center, Brigham and Women's Hospital

Boston, Massachusetts, 02130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.